7 completed, 3 not yet recruiting, 2 active not recruiting, 1 enrolling by invitation. 7 Phase 2, 6 Phase 1, 4 Phase 3.
Follow Hangzhou Highlightll Pharmaceutical Co., Ltd: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| TLL-018 in Patients With Moderate to Severe Active Rheumatoid Arthritis With Inadequate Response or Intolerance to csDMARDs TLL-018, Placebo - Rheumatoid Arthritis (RA) | Phase 2 | Enrolling by invitation | Hangzhou Highlightll Pharmaceutical Co., Ltd | 90 | 2026-09-18 | 2026-09-28 |
| A Study of Efficacy and Safety of TLL-018 in CSU Participants With Inadequate Response to 2nd-generation H1-AHs TLL-018 tablets, Placebo - Chronic Spontaneous Urticaria (CSU) | Phase 2 | Not yet recruiting | Hangzhou Highlightll Pharmaceutical Co., Ltd | 140 | 2026-09-10 | 2026-08-24 |
| A Study to Evaluate the Efficacy, Safety, and Pharmacokinetic Profiles of TLL-018 in Patients With Moderate-to-Severe Atopic Dermatitis TLL-018 tablets, Placebo - Atopic Dermatitis (AD) | Phase 2 / Phase 3 | Not yet recruiting | Hangzhou Highlightll Pharmaceutical Co., Ltd | 390 | 2026-08-31 | 2026-08-25 |
| A Phase Ib/IIa Study Assessing the Rapid Onset Characteristics of TLL-018 for Moderate-to-Severe CSU With Inadequate Response to Second-Generation H1 Antihistamines TLL-018, Placebo - Chronic Spontaneous Urticaria (CSU) | Phase 1 / Phase 2 | Not yet recruiting | Hangzhou Highlightll Pharmaceutical Co., Ltd | 36 | 2026-08-15 | 2026-08-24 |
| HL-300 Ointment in Patients With Mild-to-Moderate Atopic Dermatitis HL-300, Placebo - Atopic Dermatitis | Phase 1 / Phase 2 | Recruiting | Hangzhou Highlightll Pharmaceutical Co., Ltd | 156 | 2026-05-26 | 2026-06-23 |
| A Long-term Extension Clinical Study of TLL-018 in Patients With Rheumatoid Arthritis TLL-018 - Rheumatoid Arthritis | Phase 3 | Active not recruiting | Hangzhou Highlightll Pharmaceutical Co., Ltd | 350 | 2025-03-10 | 2026-09-25 |
| HL-300 Ointment in Healthy Volunteers HL-300 - Atopic Dermatitis | Phase 1 | Completed | Hangzhou Highlightll Pharmaceutical Co., Ltd | 36 | 2024-06-14 | 2026-07-06 |
| A Study of Efficacy and Safety of TLL-018 in CSU Participants TLL-018 tablets, Placebo tablets - Chronic Spontaneous Urticaria | Phase 3 | Active not recruiting | Hangzhou Highlightll Pharmaceutical Co., Ltd | 440 | 2024-03-27 | 2026-06-03 |
| A Phase 3 Study Comparing TLL-018 to Tofacitinib in RA Subjects With Inadequate Response or Intolerance to bDMARDs TLL-018, Tofacitinib - Rheumatoid Arthritis | Phase 3 | Completed | Hangzhou Highlightll Pharmaceutical Co., Ltd | 459 | 2023-11-15 | 2026-09-25 |
| Evaluation of TLL-018 Extended and Immediate Release Formulation for Bioequivalence Testing in Healthy Chinese Subjects TLL-018 extended-release tablet, TLL-018 immediate-release tablet - Atopic Dermatitis | Phase 1 | Completed | Hangzhou Highlightll Pharmaceutical Co., Ltd | 28 | 2023-07-12 | 2024-03-01 |
| The Efficacy and Safety of TLL018 in Moderate-to-severe Plaque Psoriasis TLL018 tablets - Plaque Psoriasis | Phase 2 | Completed | Hangzhou Highlightll Pharmaceutical Co., Ltd | 82 | 2023-01-19 | 2026-07-21 |
| Safety and Efficacy of TLL018 in Patients With Plaque Psoriasis TLL018 tablets - Moderate to Severe Plaque Psoriasis | Phase 1 | Completed | Hangzhou Highlightll Pharmaceutical Co., Ltd | 73 | 2022-06-10 | 2023-09-22 |
| Safety and Efficacy of TLL018 in Patients With Chronic Spontaneous Urticaria. TLL018 tablets - Chronic Spontaneous Urticaria | Phase 1 | Completed | Hangzhou Highlightll Pharmaceutical Co., Ltd | 41 | 2022-05-10 | 2024-03-01 |
| The Safety and Efficacy of TLL-018 in Active Rheumatoid Arthritis TLL-018, Tofacitinib - Rheumatoid Arthritis | Phase 2 | Completed | Hangzhou Highlightll Pharmaceutical Co., Ltd | 101 | 2022-02-16 | 2023-09-05 |
Arthritis, Rheumatoid (4) · Chronic Urticaria (4) · Dermatitis, Atopic (4)
tofacitinib (2)
China (11) · United States (1)
Wu Liming NA, Doctor of Medicine (1) · Zeng Xiaofeng Zeng, PhD (1)